Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
Biofrontera (Nasdaq: BFRI), a biopharmaceutical company focused on PDT development and commercialization, will release its financial results for Q3 2024 and the nine months ended September 30, 2024, after market close on November 13, 2024. The company will host a conference call to discuss the results on November 14, 2024, at 10:00 AM ET. The call will be accessible via phone and webcast for both U.S. and international participants.
Biofrontera (Nasdaq: BFRI), un'azienda biopharmaceutica focalizzata nello sviluppo e nella commercializzazione della PDT, rilascerà i suoi risultati finanziari per il terzo trimestre del 2024 e i nove mesi conclusi il 30 settembre 2024, dopo la chiusura del mercato il 13 novembre 2024. L'azienda organizzerà una conferenza telefonica per discutere i risultati il 14 novembre 2024, alle 10:00 ET. La chiamata sarà accessibile via telefono e webcast per partecipanti sia statunitensi che internazionali.
Biofrontera (Nasdaq: BFRI), una empresa biofarmacéutica enfocada en el desarrollo y comercialización de PDT, publicará sus resultados financieros para el tercer trimestre de 2024 y los nueve meses que finalizaron el 30 de septiembre de 2024, después del cierre del mercado el 13 de noviembre de 2024. La empresa llevará a cabo una llamada de conferencia para discutir los resultados el 14 de noviembre de 2024, a las 10:00 AM ET. La llamada será accesible por teléfono y por webcast para participantes tanto de EE.UU. como internacionales.
Biofrontera (Nasdaq: BFRI)는 PDT 개발 및 상업화에 중점을 둔 생물의약품 회사로, 2024년 3분기 및 2024년 9월 30일 기준 9개월 동안의 재무 결과를 2024년 11월 13일 시장 종료 후 발표할 예정입니다. 회사는 2024년 11월 14일 오전 10시(ET)에 결과를 논의하기 위한 컨퍼런스 콜을 개최합니다. 이 전화 회의는 미국 및 국제 참가자들이 전화 및 웹캐스트를 통해 접근할 수 있습니다.
Biofrontera (Nasdaq: BFRI), une entreprise biopharmaceutique axée sur le développement et la commercialisation de la PDT, publiera ses résultats financiers pour le troisième trimestre 2024 et les neuf mois se terminant le 30 septembre 2024, après la clôture du marché le 13 novembre 2024. L'entreprise organisera une conférence téléphonique le 14 novembre 2024 à 10h00 ET pour discuter des résultats. L'appel sera accessible par téléphone et par webinaire pour les participants américains et internationaux.
Biofrontera (Nasdaq: BFRI), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von PDT konzentriert, wird seine Finanz Ergebnisse für das 3. Quartal 2024 und die neun Monate bis zum 30. September 2024 nach Börsenschluss am 13. November 2024 veröffentlichen. Das Unternehmen wird am 14. November 2024 um 10:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Die Konferenz wird sowohl für Teilnehmer in den USA als auch international per Telefon und Webcast zugänglich sein.
- None.
- None.
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.
Conference Call and Webcast Information
Event: | Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call |
Date: | Thursday, November 14, 2024 |
Time: | 10:00am ET |
Conference Call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
Webcast: | Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE: Biofrontera Inc.
View the original press release on accesswire.com
FAQ
When will Biofrontera (BFRI) release Q3 2024 earnings?
When is Biofrontera's (BFRI) Q3 2024 earnings call?
How can I access Biofrontera's (BFRI) Q3 2024 earnings call?
